A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physicians Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
Study of Rigosertib in Patients with Myelodysplastic Syndrome (MDS)
Sponsor: Onconova Therapeutics Inc.
Enrolling: Male and Female Patients
IRB Number: AAAP9823
U.S. Govt. ID: NCT02562443
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine how well a drug called rigosertib works on people with MDS and to study the safety of rigosertib when it is given to people with MDS. Rigosertib is currently being tested in other clinical research studies.
This study is closed
Investigator
Mark Heaney, MD, PhD
Do You Qualify?
Are you between 18 and 79 years of age? Yes No
Have you been diagnosed with Myelodysplastic Syndrome (MDS)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE